Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

Baker McKenzie has advised STADA on the acquisition of rights to Locobase® from Karo Healthcare

Дата публикации: 05-05-2026 00:00:00



Основное содержимое страницы с новостью.

The STADA Arzneimittel AG group (“STADA”) has acquired certain rights to the Locobase® dermatology brand from Karo Healthcare, including commercial rights to the Locobase® skincare range in Denmark, Finland, Iceland, Norway and Sweden.
 
STADA is an international pharmaceutical group that focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. 
 
Locobase® is a leading brand in the dry skin market across the Nordic markets. The specialist skin brand comprises a broad portfolio addressing the needs of consumers with dry, sensitive or barrier impaired skin, including products that are used as part of the care and management of conditions such as eczema or psoriasis. 
 
Baker McKenzie acted as legal adviser to STADA working closely with the STADA in-house legal team represented by Marcus Heppner (Director Legal Affairs) and Anna-Maria Krekeler (Associate Director Legal). Baker McKenzie was represented by a core team consisting of Katja Persson, Daniel Högström and Joan Sardar and supporting lawyers including Seher Budak, William Höglund, Annika López Kasteskog, Peder Oxhammar, Emelie Ageby Svensson (all Stockholm) and Christian Atzler and Frank Pflueger (both Frankfurt).

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Baker McKenzie advises on the sale of Vitabiotics to Bain Capital01027-07-2026
2Baker McKenzie Advises on Memo Therapeutics' Sale to Ipsen and Related Carve-Out018.3301-07-2026
3Baker McKenzie Advises Chemomab on Merger with Scipher Medicine01010-07-2026
4Baker McKenzie Advises Merit Medical on the Acquisition of View Point Medical08.407-04-2026
5Baker McKenzie Advises Bain Capital Life Sciences on Investment in Swixx BioPharma01005-06-2026
6Baker McKenzie Advises Bayer on USD 2.45 billion Acquisition of Perfuse Therapeutics018.3306-05-2026
7Baker McKenzie Advises Joint Bookrunners on Sunway Healthcare’s MYR 3.28 Billion IPO018.3318-03-2026
8Baker McKenzie Advises Sino Biopharm on up to US$1.53 Billion Exclusive License Agreement with Sanofi for Rovadicitinib015.8812-03-2026
9Baker McKenzie Advises a Consortium led by SPE Capital, and included EBRD, Proparco and BIO on their Investment in Leading Ophthalmic Pharmaceutical Manufacturer09.1501-04-2026
10Baker McKenzie Acts as Global Counsel to Medtronic plc on the Carve-out and Spin-off of their Diabetes business, MiniMed Group, Inc. 019.5211-03-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10. Источник: www.bakermckenzie.com.